• ExpreS2ion reported a positive safety review in its Phase I ES2B-C001 study in advanced HER2-expressing breast cancer.
• The monitoring board flagged no dose-limiting toxicities, enabling the top-dose cohort to expand by three additional patients.
• Early data already presented showed broad immune responses across evaluable patients, supporting continued development without raising new safety concerns.
• The Phase I primary readout remains scheduled for end-2026, with results to be presented in the future.
• Phase II initiation shifted to the second half of 2027 to incorporate planned regulatory feedback in Europe and the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ExpreS2ion Biotech Holding AB published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.